The road to find an effective treatment for Alzheimer’s has been long and tortured. Established industry titans have spent many years developing promising drugs, only to see them fail in late-stage trials.

NeuroTherapia Inc., a Cleveland Clinic spinoff, is trying a new approach. Instead of targeting the amyloid plaques thought to contribute to Alzheimer’s disease, NeuroTherapia is focusing on the role of microglia, cells within the central nervous system that cause uncontrolled inflammation.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Reducing inflammation is a promising approach to Alzheimer’s disease. In addition to drugs that could turn off the inflammatory mechanism, research needs to pay much more attention to the multiple triggers that can turn it on. There is anecdotal evidence there are a wide variety of triggers (for which impacts can vary with genetics), including mercury and aluminum, chemicals and pesticides, molds/mycotoxins, and bacteria and viruses.

    • So if they knew this, why put these in vaccines?
      Why are so many people young and old coming down with this nerve damaged disorder named Alzheimer’s?

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.